Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a nonrandomized, open-label study to evaluate the efficacy and safety of combination
treatment of Nilotinib and RAD001 in the treatment of c-kit + AML. Patients refractory to
standard chemotherapy or not eligible to standard chemotherapy can be included. Patients will
be treated with 400 mg Nilotinib bid (total daily dose 800 mg). RAD001 will be added after a
treatment duration of 1 week in a dosage of 2,5 mg/day. Treatment duration will be 25 weeks.